Navigation Links
Compendia Bioscience Announces the Release of Oncomine 4 Research Edition
Date:9/23/2009

ANN ARBOR, Mich., Sept. 23 /PRNewswire-USNewswire/ -- Compendia Bioscience, Inc. today announced the release of Oncomine Research Edition version 4.2, a significant product upgrade for the academic and non-profit communities. Since its inception, Compendia has been fully committed to supporting academic and non-profit cancer research efforts worldwide. This new version of Oncomine features a completely redesigned user-interface, improved search and filter capabilities, and several other new features designed to make gene discovery and validation simpler and more efficient.

Cancer researchers have made Oncomine the industry standard with over 12,000 academic users. These researchers use Oncomine to discover new genes, evaluate pathways and better understand specific cancer types resulting in the publication of more than 200 peer reviewed journal articles. Oncomine has led to several major cancer research discoveries such as the recent publication of AGTR1 overexpression and sensitivity to losartan in breast cancer (Proc Natl Acad Sci U S A. 2009 Jun 1).

"We are really pleased to release this exciting new version of Oncomine to the academic research community," said Compendia's Co-Founder and CEO Dan Rhodes, Ph.D. "We are confident that Oncomine 4 will continue to accelerate cancer research and lead to important new discoveries."

New Features and Capabilities in Oncomine 4 Research Edition

  • Unified interface, optimizing workflows with rapid navigation and visualization of results through three interactive panes
  • Smart search and browse, giving users the ability to search multiple terms within a single instance
  • The Compendia Ontology, standardizing a set of rules used to characterize Oncomine data, which drives consistent downstream analyses
  • Standardized analyses, comparing gene expression profiles between norma
    '/>"/>

SOURCE Compendia Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Compendia Bioscience Announces the Receipt of a $2.4M SBIR Award and Related Management Changes
2. Compendia Bioscience Announces the Release and Availability of Oncomine(TM) Research Premium Edition
3. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
4. On Third Anniversary, Compendia Bioscience Announces Continued Revenue Growth, Major Long-Term Customer Contracts and Forecasts Profitability
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... Food and Drug Administration (FDA) rare pediatric disease priority ... (BLA) submission for alirocumab.  The priority review voucher entitles ... which provides for an expedited 6-month review from the ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... and aesthetic plastic surgeryMEDFORD, Mass., Feb. 25 ... device company developing silk-based biomaterial platforms for ... 510(k) clearance from the U.S. Food and ... (TM) silk-based, long term bioresorbable scaffold technology."We ...
... Technologies Inc. (IVT), a vaccine development company, has ... of Allergy and Infectious Diseases (NIAID) at the ... The research collaboration involves formulating NIAID antigens in ... vaccines for HIV and malaria. , "NIAID is ...
... results for the year ending 31,December 2008. , , 2008 ... intravenous iclaprim in US, - Restructuring and focus ... II trial with oral, iclaprim, ... Share placing, Cash and financial investments of CHF 38.7 million ...
Cached Biology Technology:Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 2Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 3Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 4ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria 2Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5
(Date:7/30/2014)... Scientists studying the potential effects of climate change ... focusing on the wrong factors, according to a ... Wildlife Conservation Society, University of Queensland, and other ... conservation science is missing the point when it ... majority of climate change scientists focus on the ...
(Date:7/30/2014)... its new relationship with the International College of Neuropsychopharmacology ... to publish International Journal of Neuropsychopharmacology ( ... Frazer, Editor-in-Chief of IJNP said, "Our belief ... further facilitate the goal for the IJNP ... neuropsychopharmacology. The conversion of the IJNP to ...
(Date:7/30/2014)... ALBANY, New York , July 30, 2014 ... up-to-date research on Global Government Biometric Systems ... Analysis. The Global Biometric Systems Market ... global biometric systems market over the next ten ... industry, using detailed market size forecasts. ...
Breaking Biology News(10 mins):Conservation scientists asking wrong questions on climate change impacts on wildlife 2OUP to partner with the International College of Neuropsychopharmacology 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... majority of the abstracts to be presented at the EORTC-NCI-AACR [1] ... two weeks before the meeting at 00.01 hrs CET on Friday ... Journalists are free to report on the online abstracts from ... they should bear in mind that all the abstracts had to ...
... Richmond, Va. (Oct. 27, 2010) If you ... A recent study conducted by researchers from Virginia Commonwealth ... cancer patients who were eligible for genetic testing never ... relative,s life. The research, "Exploring Hereditary Cancer ...
... SHORES, Calif., Oct. 27 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
Cached Biology News:Abstracts for the EORTC-NCI-AACR Symposium in Berlin go up online on Friday, Oct. 29 2Knowledge of genetic cancer risks often dies with patients, finds VCU Massey Cancer Center 2CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 2CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 3CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 4CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 5CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 6CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 7CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 8CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 9CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 10
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Rab1A...
Biology Products: